AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease
AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 clinical trial for AGB101, a promising treatment for amnestic Mild Cognitive Impairment (MCI) caused by Alzheimer’s Disease (AD). The trial, named HOPE4MCI, aims to assess the efficacy and safety of […]